MajorDirect thrombin inhibitor×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
Dabigatran etexilate is a substrate of the transporter P-glycoprotein (P-gp), and the European SmPC expects P-gp inhibitors to raise dabigatran levels (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). In vitro, tacrolimus inhibited P-gp about as strongly as itraconazole and ciclosporin. But limited clinical data with everolimus, another P-gp substrate, suggest weaker inhibition than with strong P-gp inhibitors (EMA). Dabigatran and tacrolimus have not been studied together, so the size of any rise in dabigatran levels is unknown (EMA). Dabigatran leaves the body mainly unchanged in the urine, and in moderate renal impairment its exposure is about 2.7-fold higher (EMA). Tacrolimus can impair renal function in transplant recipients (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
Higher dabigatran levels mean a higher risk of bleeding (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Dabigatran can cause nosebleeds, gastrointestinal bleeding and haematomas, and less often intracranial haemorrhage. An unexplained fall in haemoglobin, haematocrit or blood pressure may point to hidden bleeding (EMA). Impaired renal function is a very common adverse effect of tacrolimus and can be as severe as acute renal failure (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It usually shows only on blood tests.
Management
The combination is not recommended. The European dabigatran summary of product characteristics (SmPC) lists tacrolimus among drugs not recommended with dabigatran (dabigatran SmPC, European Medicines Agency, EMA). It contraindicates only strong P-glycoprotein (P-gp) inhibitors from a closed list: systemic ketoconazole, ciclosporin, itraconazole, dronedarone and glecaprevir/pibrentasvir (EMA). The European Heart Rhythm Association (EHRA) practical guide marks this pair as not advisable, with reference to the dabigatran SmPC (EHRA 2021). The US dabigatran label does not name tacrolimus. It says to avoid P-gp inhibitors in atrial fibrillation at creatinine clearance 15–30 mL/min. In the treatment and prevention of deep vein thrombosis and pulmonary embolism, it says to avoid them at creatinine clearance below 50 mL/min (dabigatran label, US Food and Drug Administration, FDA). Assess creatinine clearance before starting dabigatran, which is contraindicated below 30 mL/min (EMA). During treatment, check renal function whenever a decline is suspected, including with some concomitant drugs, and stop dabigatran in acute renal failure (EMA). Closely monitor people with impaired renal function who take tacrolimus, because the tacrolimus dose may need to be reduced (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During dabigatran treatment, watch for signs of bleeding and anaemia, and if severe bleeding occurs, stop dabigatran and look for the cause (EMA). Diluted thrombin time, ecarin clotting time and activated partial thromboplastin time (aPTT) can help detect excessive dabigatran exposure. The international normalised ratio (INR) gives false-positive rises with dabigatran and should not be measured (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Pradaxa (dabigatran etexilate) capsules prescribing information (2025)– FDA label, DailyMed setid ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, sections 2.2, 5.5, 7.1–7.3, figure 3.1
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Dabigatrán etexilato (EU/1/08/442), sección 4.3 (2025)– EMA, Pradaxa 110 mg cápsulas duras (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442005, información del producto de la EMA actualizada 24/11/2025, secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- EMA: Ficha técnica: Dabigatrán etexilato (EU/1/08/442), sección 4.5 (2026)– EMA, Pradaxa 110 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442005, consultada 28.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4, 4.5 (tabla 9), 4.8 y 5.2